Moors & Cabot Inc. boosted its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 235.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,750 shares of the medical equipment provider’s stock after purchasing an additional 70,740 shares during the quarter. Moors & Cabot Inc.’s holdings in Boston Scientific were worth $4,398,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Compass Capital Management Inc. grew its position in shares of Boston Scientific by 16.9% during the 3rd quarter. Compass Capital Management Inc. now owns 1,004,548 shares of the medical equipment provider’s stock valued at $43,849,000 after buying an additional 145,018 shares during the last quarter. SVB Wealth LLC raised its stake in Boston Scientific by 457.7% during the third quarter. SVB Wealth LLC now owns 31,868 shares of the medical equipment provider’s stock worth $1,391,000 after acquiring an additional 26,154 shares during the period. Russell Investments Group Ltd. raised its stake in Boston Scientific by 10.8% during the third quarter. Russell Investments Group Ltd. now owns 3,207,330 shares of the medical equipment provider’s stock worth $140,024,000 after acquiring an additional 311,634 shares during the period. Eurizon Capital SGR S.p.A. lifted its holdings in Boston Scientific by 31.9% in the third quarter. Eurizon Capital SGR S.p.A. now owns 1,596,301 shares of the medical equipment provider’s stock worth $69,766,000 after acquiring an additional 386,008 shares during the last quarter. Finally, PBU The Pension Fund of Early Childhood & Youth Educators lifted its holdings in Boston Scientific by 18.8% in the third quarter. PBU The Pension Fund of Early Childhood & Youth Educators now owns 263,677 shares of the medical equipment provider’s stock worth $11,510,000 after acquiring an additional 41,713 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts have commented on BSX shares. Stifel Nicolaus decreased their target price on Boston Scientific from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, October 26th. UBS Group dropped their price target on Boston Scientific from $67.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, October 29th. Sanford C. Bernstein cut their price target on Boston Scientific from $54.00 to $49.00 and set an “outperform” rating on the stock in a report on Thursday, October 29th. Mizuho set a $50.00 price objective on Boston Scientific in a research report on Thursday, October 29th. Finally, Citigroup reduced their price objective on Boston Scientific from $48.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $61.43.
View Our Latest Stock Analysis on BSX
Boston Scientific Stock Performance
BSX opened at $44.33 on Monday. The company has a current ratio of 1.36, a quick ratio of 0.81 and a debt-to-equity ratio of 0.42. The business’s 50 day moving average is $44.00 and its 200-day moving average is $54.50. The stock has a market cap of $64.25 billion, a PE ratio of 18.78, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. Boston Scientific Corporation has a twelve month low of $39.57 and a twelve month high of $104.61.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same period in the prior year, the company posted $0.75 EPS. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. On average, analysts predict that Boston Scientific Corporation will post 3.17 earnings per share for the current year.
About Boston Scientific
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Recommended Stories
- Five stocks we like better than Boston Scientific
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
